BioSpace News Archive

Indivior PLC will hold a Capital Markets Day in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company’s strategic growth plans and roadmap for delivering long-term shareholder value.

Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19.

A new treatment is significantly more effective in improving symptoms of moderate to severe hip osteoarthritis in dogs than glucocorticoid alone, according a study published this week in “Advances in Diagnostic and Treatment Methods for Joint Diseases in Dogs and Cats,” a special issue published by the veterinary journal Animals.

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, to dramatically accelerate the enzyme discovery and development process.

Replimune Group, Inc. today announced that the Company has entered into a Master Clinical Trial Collaboration and Supply Agreement in relation to Replimune’s RP2/3 program in colorectal cancer (CRC) and hepatocellular carcinoma (HCC).

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, as submitted for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years or older.

Replimune Group, Inc. today announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.

Element Biosciences, Inc. announced Avidity Cloudbreak technology, improvements to chemistry kits for the current Element AVITI™ System that reduce run times and enable even more applications.

Willow Biosciences Inc., a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn.

RayzeBio, Inc. appointed Rich Heyman, Ph.D. as chair of the board of directors. Dr. Heyman is an accomplished biotechnology veteran with over 25 years of operational experience.